---
title: The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL
  via antibody-dependent cellular phagocytosis
date: '2024-03-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38518105/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240323180632&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation
  of precursor B or T cells (BCP- or T-ALL). Current treatment protocols obtain high
  cure rates in children but are based on toxic polychemotherapy. Novel therapies
  are urgently needed, especially in relapsed/refractory (r/r) disease, high-risk
  leukemias and T-ALL, where immunotherapy approaches remain scarce. While the Interleukin-7
  receptor (IL-7R) plays a pivotal role in ALL development, no ...
disable_comments: true
---
Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of precursor B or T cells (BCP- or T-ALL). Current treatment protocols obtain high cure rates in children but are based on toxic polychemotherapy. Novel therapies are urgently needed, especially in relapsed/refractory (r/r) disease, high-risk leukemias and T-ALL, where immunotherapy approaches remain scarce. While the Interleukin-7 receptor (IL-7R) plays a pivotal role in ALL development, no ...